GCNT1 and prostate cancer: In addition, while the in vivo studies reported here were carried out using immunocompromised mouse models, moving forward, and as GCNT1 can upregulate sLeX (a Selectin ligand linked to tumour metastasis which is recognised by endothelial cells and lymphocytes43–45,58,59), it will be also important to study the role of GCNT1 in prostate cancer metastasis in the context of a functional immune system.